Business
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
-Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platf
About this update from Benitec Biopharma Inc.
[{"type":"image","alt":"Benitec Biopharma Inc.","displaySize":"","headline":null,"caption":"Benitec Biopharma Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/272fa36373841b48b583df523fcc23c2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.vghzh1j1T_tsLVz3EmMLQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/272fa36373841b48b583df523fcc23c2","width":300,"height":95}},"lazy":false},{"type":"text","content":"-Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-","length":199,"tagName":"p"},{"type":"text","content":"HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announces the appointment of Dr. Sharon Mates to the board of directors (BOD) of the Company, effective November 2, 2025.","length":437,"tagName":"p"},{"type":"text","content":"“We are delighted to welcome Dr. Sharon Mates to Benitec’s Board of Directors,” said Jerel Banks, M.D., Ph.D., Chairman and Chief Executive Officer of Benitec Biopharma. “Dr. Mates brings exceptional leadership experience in building successful biotechnology companies and advancing innovative therapies from discovery through commercialization. Her extensive track record of building value in the biotechnology sector will be invaluable as we continue progressing our BB-301 program in Oculopharyngeal Muscular Dystrophy (OPMD) towards regulatory approval and expanding the potential of our ddRNAi therapy platform into other therapeutic indications.”","length":657,"tagName":"p"},{"type":"text","content":"“I am pleased to join the Board of Directors at Benitec Biopharma during this critical period in the Company’s evolution,” said Dr. Sharon Mates. “Benitec’s innovative silence and replace platform holds tremendous potential, and BB-301 represents the potential first of its kind gene therapy for addressing a serious unmet medical need. I look forward to working with th...